Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials

Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip